The complex ways through which p66Shc can interfere with critical signalling pathways, such as PI3K/Akt, MAPK and NF‐κB, underscore its potential as a therapeutic target and biomarker in various types of cancers, including breast, colorectal, lung and melanoma. This evidence concerns the gene AKT1 and melanoma.